Table 2.
The ovarian reserve in BPES patients with and without FOXL2 mutations.
| Characteristics | Mutation group | Nonmutation group | P |
|---|---|---|---|
| N | 17 | 4 | – |
| Age (y) | 30.06 ± 4.66 | 29.25 ± 2.22 | 0.742 |
| BMI (kg/m2) | 24.81 ± 3.34 | 24.18 ± 0.23 | 0.716 |
| Duration of infertility (y) | 5.29 ± 3.71 | 4.63 ± 3.38 | 0.746 |
| FSH (IU/L) | 17.08 ± 12.74 | 6.66 ± 1.86 | 0.007 |
| LH (IU/L) | 11.00 ± 5.76 | 3.23 ± 1.56 | 0.017 |
| E2 (pg/mL) | 38.86 ± 20.22 | 29.33 ± 16.27 | 0.396 |
| T (ng/dL) | 28.22 ± 14.46 | 14.84 ± 11.73 | 0.149 |
| AMH (ng/mL) | 0.460 (0.170, 0.858) | 2.295 (1.120, 4.518) | 0.012 |
| AFC | 8.18 ± 5.13 | 15.25 ± 1.71 | 0.015 |
| Prevalence of irregular menstruation, % (n/N) | 76.47% (13/17) | 0 (0/4) | 0.012 |
Data are expressed as the mean ± standard deviation or median (interquartile range).
BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; T, testosterone; AMH, anti-müllerian hormone; AFC, antral follicle count.